Clinical Trial

Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of vaccines encoding the RSV monovalent antigen or the Flu hemagglutinin subtype 5 (H5) antigen in healthy participants aged 18 to 49 years. The total duration of study participation for each participant varies by stage and treatment arm. Stage 1: * For Arm 1, Arm 2, and Arm 3 the duration of study participation will be approximately 7 months for each participant. * For Arm 4, Arm 5, and Arm 6 the duration of study participation will be approximately 6 months for each participant. Stage 2: For all arms, the duration of study participation will be approximately 7 months for each participant.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-05-09
notable Trial sites expanded: 0 -> 6 locations 2026-05-09
Trial Details
NCT Number NCT07516418
Lead Sponsor Sanofi
Conditions Respiratory Syncytial Virus (RSV), Influenza A(H5N1)
Enrollment 570 participants
Start Date 2026-04-15
Primary Completion 2027-04-04 (estimated)
Study Completion 2027-04-04 (estimated)
Updated on ClinicalTrials.gov 2026-05-08